Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Axon Therapies, Inc.
- Study ID
- NCT04592445
- Status
- Recruiting
Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF
Eligibility Criteria
- Sex
- ALL
- Age
- 40 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Greater Splanchnic Nerve Ablation — DEVICEThe greater splanchnic nerve (GSN) ablation procedure begins with a small needle puncture in the groin or neck to access a vein, using methods that are commonly used for heart procedures. Doctors then guide thin tubes and wires through the vein to reach a nerve called the right greater splanchnic nerve. X-ray imaging is used to help the doctor see where the catheter is and guide it to the correct location. Once the catheter is in the right place, the doctor uses the device to treat the nerve using controlled heat.
- Sham Control — DEVICEDuring the sham procedure, a small needle puncture will be made in the groin or neck to access a vein using standard medical techniques. A short tube will be placed into the vein, similar to what is done for many heart procedures. The Satera catheter and treatment devices will not be inserted, and the nerve will not be treated. The procedure will take about the same amount of time as the treatment procedure.
Study Details
The purpose of this clinical study is to evaluate the safety and early effectiveness of a catheter-based procedure that treats a nerve called the right greater splanchnic nerve. The study includes people who have heart failure with preserved ejection fraction (HFpEF). The goal is to learn whether this procedure, performed using the Satera Ablation System, may help improve symptoms and to better understand which patients may benefit most from this treatment in the future.
Key Dates
- Start date
- Dec 18, 2020
- Status verified
- Mar 2026
- Primary completion
- Jan 10, 2028
- Completion
- Aug 10, 2029
Study Design
- Enrollment
- 150 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Greater Splanchnic Nerve AblationAfter anesthesia is given, doctors will use the Satera Ablation System to reach a nerve called the right greater splanchnic nerve. Subjects receive catheter-based unilateral ablation of the right greater splanchnic nerve.
- Sham Comparator: Sham Control ArmAfter anesthesia is given, doctors will place a small tube into a vein. The steps and length of the procedure will be similar to the Axon treatment procedure, but the study treatment will not be performed.
Primary Outcome Measure
Primary Safety Endpoint: Device or procedure related serious adverse events [ Time Frame: 1 Month ]
Central Contacts
- Judit Adorjan16507221119
- Jennifer Moore, MS
Locations (20)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Cardiology PC | Birmingham | Alabama | 35211 | - |
| Arizona Cardiovascular Research Center | Phoenix | Arizona | 85016 | - |
| Scripps Health | La Jolla | California | 92037 | - |
| University of California, San Francisco | San Francisco | California | 94143 | Liviu Klein, MD (PRINCIPAL_INVESTIGATOR) |
| Bluhm Cardiovascular Institute of Northwestern University | Chicago | Illinois | 60611 | Daniel Roshevsky Ravi Patel, MD (PRINCIPAL_INVESTIGATOR) |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | Adaeze Emeka Mark Nathan Belkin, MD (PRINCIPAL_INVESTIGATOR) |
| Prairie Education and Research Cooperative | Springfield | Illinois | 62701 | - |
| Ascension St. Vincent - Cardiovascular Research Institute | Indianapolis | Indiana | 46260 | - |
| Cardiovascular Institute of the South | Houma | Louisiana | 70360 | Kimberly Lirette Peter Fail, MD (PRINCIPAL_INVESTIGATOR) |
| Michigan Medicine, University of Michigan | Ann Arbor | Michigan | 48109 | Scott Hummel, MD (PRINCIPAL_INVESTIGATOR) |
| Mayo Clinic | Rochester | Minnesota | 55905 | Alyssa Ploof Barry Borlaug, MD (PRINCIPAL_INVESTIGATOR) |
| St. Louis Heart and Vascular | St Louis | Missouri | 63136 | Melissa McCann Gil Vardi, MD (PRINCIPAL_INVESTIGATOR) |
| Columbia University Medical Center | New York | New York | 10032 | Nir Uriel, MD (PRINCIPAL_INVESTIGATOR) |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | - |
| Weill Cornell Medicine | New York | New York | 10021 | Caroline Goldstein Parag Goyal, MD (PRINCIPAL_INVESTIGATOR) |
| Rochester General Hospital | Rochester | New York | 14621 | Kathleen Ebeling, RN Scott Feitell, DO (PRINCIPAL_INVESTIGATOR) |
| Duke University Medical Center | Durham | North Carolina | 27710 | Matthew Gray Marat Fudim, MD, MHS (PRINCIPAL_INVESTIGATOR) |
| Ohio State University Wexner Medical Center | Columbus | Ohio | 43210 | Kalyn Ferguson Alexandria Miller, MD (PRINCIPAL_INVESTIGATOR) |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | Elly Borhanian Sheldon Litwin, MD (PRINCIPAL_INVESTIGATOR) |
| Virginia Commonwealth University Medical Center | Richmond | Virginia | 23298 | - |
Find similar trials in Birmingham, AL
By research site